v3.5.0.2
Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2012
Jun. 30, 2016
USD ($)
shares
Jun. 30, 2015
USD ($)
Tranche
Jun. 30, 2016
USD ($)
Segment
shares
Jun. 30, 2015
USD ($)
Tranche
shares
Dec. 31, 2015
USD ($)
shares
Nov. 30, 2015
USD ($)
Mar. 05, 2015
USD ($)
Dec. 31, 2014
shares
May 31, 2014
USD ($)
Dec. 31, 2012
USD ($)
Dec. 06, 2012
USD ($)
Significant Accounting Policies [Line Items]                        
Sales discount percentage   2.00%   2.00%                
Sales discount term       30 days                
Trade receivables, credit period       30 days                
Number of tranches for private placement transaction | Tranche     2   2              
Accounts receivable written off   $ 0   $ 0                
Other long-term assets   $ 174,000   $ 174,000   $ 174,000            
Warrants outstanding | shares   0   0                
Gain (loss) on change in fair value of derivative liability   $ 5,810,000 $ (600,000) $ 4,560,000 $ (136,000)              
Number of operating segments | Segment       1                
BioPharma Debt                        
Significant Accounting Policies [Line Items]                        
Maximum repayment of future revenue and receivables   132,100,000   $ 132,100,000               $ 150,000,000
Fair value of embedded derivative liability                       $ 14,600,000
Gain (loss) on change in fair value of derivative liability       2,700,000 (800,000)              
Preferred Stock Purchase Option                        
Significant Accounting Policies [Line Items]                        
Gain (loss) on change in fair value of derivative liability         (946,000)              
Derivative liability at fair value               $ 900,000        
Embedded Derivative Financial Instruments                        
Significant Accounting Policies [Line Items]                        
Gain (loss) on change in fair value of derivative liability       4,560,000 $ 700,000              
Embedded Derivative Financial Instruments | BioPharma Debt                        
Significant Accounting Policies [Line Items]                        
Maximum repayment of future revenue and receivables                     $ 150,000,000  
Fair value of embedded derivative liability   2,800,000   2,800,000   5,500,000            
Gain (loss) on change in fair value of derivative liability       $ 2,700,000                
Top Three Customers | Gross Product Sales | Customer Concentration Risk                        
Significant Accounting Policies [Line Items]                        
Concentration risk percentage       95.00% 95.00%              
Top Three Customers | Accounts Receivable | Customer Concentration Risk                        
Significant Accounting Policies [Line Items]                        
Concentration risk percentage       94.00% 96.00%              
Convertible Debt | 2014 Notes                        
Significant Accounting Policies [Line Items]                        
Convertible senior notes, discount                   $ 27,900,000    
Fair value of embedded derivative liability   600,000   $ 600,000   2,100,000            
Gain (loss) on change in fair value of derivative liability       1,500,000 $ 1,500,000 1,500,000            
Derivative liability at fair value                   $ 3,500,000    
Convertible Debt | 2015 Notes                        
Significant Accounting Policies [Line Items]                        
Convertible senior notes, discount             $ 3,800,000          
Fair value of embedded derivative liability   200,000   200,000   600,000            
Gain (loss) on change in fair value of derivative liability       $ 400,000   $ 400,000            
Derivative liability at fair value             $ 500,000          
Convertible Debt | 2014 Notes and 2015 Notes                        
Significant Accounting Policies [Line Items]                        
Derivative liability fair value assumptions, dividend yield       20.60%   25.60%            
Derivative liability fair value assumptions, risk-free rate       2.00%   2.90%            
Derivative liability fair value assumptions, volatility rate       86.00%   89.00%            
Convertible Debt | 2012 Notes                        
Significant Accounting Policies [Line Items]                        
Convertible senior notes, discount   0   $ 0   $ 0            
Note, expected term 24 months                      
Non Cash | Convertible Debt | 2014 Notes                        
Significant Accounting Policies [Line Items]                        
Convertible senior notes, discount   20,700,000   20,700,000   24,100,000            
Non Cash | Convertible Debt | 2015 Notes                        
Significant Accounting Policies [Line Items]                        
Convertible senior notes, discount   $ 3,600,000   $ 3,600,000   $ 4,200,000            
Warrants Issued October 2009                        
Significant Accounting Policies [Line Items]                        
Warrants outstanding | shares   0   0   0     8,087,388      
Warrants exercised | shares         1,844,585              
Warrants expired | shares         6,242,803              
Accounting Standards Update 2015-03 | Convertible Debt | 2014 Notes                        
Significant Accounting Policies [Line Items]                        
Other long-term assets           $ (1,800,000)            
Accounting Standards Update 2015-03 | Convertible Debt | 2015 Notes                        
Significant Accounting Policies [Line Items]                        
Other long-term assets           (100,000)            
Accounting Standards Update 2015-03 | Scenario, Adjustment                        
Significant Accounting Policies [Line Items]                        
Other long-term assets           (1,900,000)            
Unamortized debt issuance cost           $ 1,900,000            
ASU No. 2016-09                        
Significant Accounting Policies [Line Items]                        
Excess tax provision on stock-based awards   $ 100,000   $ 200,000                
Deferred tax assets   $ 1,600,000   $ 1,600,000                
ASU No. 2016-09 | Scenario, Previously Reported                        
Significant Accounting Policies [Line Items]                        
Excess tax provision on stock-based awards         $ (600,000)              
ASU No. 2016-09 | Restatement Adjustment                        
Significant Accounting Policies [Line Items]                        
Excess tax provision on stock-based awards         $ 600,000              
Minimum | Embedded Derivative Financial Instruments | BioPharma Debt                        
Significant Accounting Policies [Line Items]                        
Derivative liability fair value assumptions, term       1 year 7 months 6 days   2 years            
Derivative liability fair value assumption, coupon rate       6.60%   6.60%            
Derivative liability fair value assumptions, market yields       11.00%   13.00%            
Maximum | Embedded Derivative Financial Instruments | BioPharma Debt                        
Significant Accounting Policies [Line Items]                        
Derivative liability fair value assumptions, term       5 years 10 months 24 days   7 years 3 months 18 days            
Derivative liability fair value assumption, coupon rate       12.50%   12.50%            
Derivative liability fair value assumptions, market yields       27.70%   30.70%